Replimune said it reached alignment with the U.S. FDA to resubmit its melanoma biologic RP-1 (vusolimogene oderparepvec) after two prior rejections. The company plans to file the biologics license application again for RP-1 in combination with nivolumab in advanced melanoma and said the agency intends to treat the resubmission as an urgent matter upon receipt. The FDA’s previous complete response letters cited insufficient data, and the company’s updated discussions come against a backdrop of FDA leadership change, including the exit of former CDER/CBER leadership and the resignation of FDA commissioner Marty Makary noted in the coverage. Investors were immediately reacting to the pathway back to review, with shares surging reported after the announcement. The resubmission matters for the broader oncology landscape because it tests how quickly the FDA will revisit high-profile, controversial modality programs when data gaps are addressed. It also underscores that combination strategy and the evolving regulatory environment can shape whether developers regain momentum after refusals. Biotech stakeholders will watch whether Replimune supplements with additional analyses, endpoints, or bridging datasets sufficient for approval on the combination regimen sought.